Morishita Jintan Co., Ltd. AI Stock Analysis
Want to see JP:4524 full AI Analyst Report?
Morishita Jintan Co., Ltd. (4524) AI Stock Analysis
Morishita Jintan Co., Ltd.
(TSE/TYO:4524)
The company's financial stability is a key strength, anchored by a very conservative balance sheet with low debt. However, this is offset by modest profitability, recent revenue softness, and minimal free cash flow due to heavy reinvestment. Technical indicators show a neutral trend, while the low P/E ratio and solid dividend yield provide some valuation support. Overall, the stock presents a stable but low-growth profile.
Morishita Jintan Co., Ltd. (4524) vs. iShares MSCI Japan ETF (EWJ)
- Market Cap
- JPY 9.03B
- Dividend Yield
- 2.95%
- Average Volume (3M)
- 1,591
- Price to Earnings (P/E)
- 10.3
- Beta (1Y)
- 0.32
- Revenue Growth
- -0.47%
- EPS Growth
- 50.82%
- Country
- Japan
- Employees
- 359
- Sector
- Healthcare
- Sector Strength
- 51
- Industry
- Drug Manufacturers - Specialty & Generic
Morishita Jintan Co., Ltd. Business Overview & Revenue Model
Company Description
Morishita Jintan Co., Ltd. is a Japanese enterprise that manufactures and distributes a diverse array of products, encompassing pharmaceuticals, quasi-pharmaceuticals, medical devices, and food items. The company's operations are divided into two mai...
How the Company Makes Money
Morishita Jintan generates revenue primarily by selling branded consumer healthcare products. Key revenue streams include: (1) Direct product sales: Income from the sale of its own branded health-related products (e.g., mouth/throat care items, suppl...
Morishita Jintan Co., Ltd. Financial Statement Overview
Summary
The balance sheet is very strong (Score 85) with minimal debt, but the income statement (Score 60) shows modest profitability and recent revenue decline, while cash flow (Score 50) is constrained by high capex. The overall financial picture is stable but growth and cash generation are limited.
Income Statement
60NeutralBalance Sheet
85Very PositiveCash Flow
50Neutral| Breakdown | TTM | Mar 2026 | Mar 2025 | Mar 2024 | Mar 2023 | Mar 2022 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 12.82B | 12.69B | 12.77B | 12.41B | 11.36B | 9.56B |
| Gross Profit | 6.23B | 5.93B | 5.79B | 6.00B | 5.31B | 4.88B |
| EBITDA | 1.54B | 1.29B | 1.36B | 1.29B | 1.25B | 977.00M |
| Net Income | 789.00M | 628.00M | 547.00M | 697.00M | 491.00M | 283.00M |
Balance Sheet | ||||||
| Total Assets | 18.62B | 18.62B | 17.90B | 17.18B | 16.10B | 14.48B |
| Cash, Cash Equivalents and Short-Term Investments | 1.52B | 1.83B | 1.94B | 1.09B | 2.41B | 2.14B |
| Total Debt | 1.75B | 1.76B | 1.36B | 270.00M | 469.00M | 749.00M |
| Total Liabilities | 5.65B | 5.64B | 5.74B | 5.04B | 4.71B | 4.02B |
| Stockholders Equity | 12.97B | 12.98B | 12.15B | 12.14B | 11.39B | 10.46B |
Cash Flow | ||||||
| Free Cash Flow | 0 | 18.00M | 69.00M | -455.00M | 715.00M | -159.00M |
| Operating Cash Flow | 0 | 1.15B | 669.00M | 196.00M | 1.18B | 543.00M |
| Investing Cash Flow | 0 | -1.23B | -701.00M | -1.15B | -474.00M | -463.00M |
| Financing Cash Flow | 0 | -30.00M | 880.00M | -362.00M | -433.00M | -645.00M |
Morishita Jintan Co., Ltd. Technical Analysis
Price Trends
Market Momentum
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For JP:4524, the sentiment is Positive. The current price of 2206.00 is above the 20-day moving average (MA) of 2198.05, below the 50-day MA of 2219.54, and below the 200-day MA of 2209.89, indicating a neutral trend. The MACD of -3.18 indicates Negative momentum. The RSI at 50.29 is Neutral, neither overbought nor oversold. The STOCH value of 69.37 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for JP:4524.
Morishita Jintan Co., Ltd. Peers Comparison
Overall Rating
JP:454070Outperform
JP:453863Neutral
JP:452462Neutral
JP:292957Neutral
JP:451245Neutral
Financial Indicators
| Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
| 70Outperform | JPY 303.35B | 9.28 | 9.84% | 3.98% | 13.32% | 17.39% | |
| 63Neutral | JPY 19.02B | 8.33 | ― | 4.15% | 2.29% | ― | |
| 62Neutral | JPY 9.00B | 10.30 | ― | 2.95% | -0.47% | 50.82% | |
| 57Neutral | JPY 15.88B | 8.02 | ― | 4.01% | -3.12% | 406.78% | |
| Sector * | 51Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% |
| 45Neutral | JPY 10.13B | 56.26 | ― | 1.20% | 23.41% | 149.71% |
* Healthcare Sector Average
Performance Comparison
| Show on chart | Ticker | Company Name | Price | Change | % Change |
|---|---|---|---|---|---|
| JP:4524 | Morishita Jintan Co., Ltd. | 2206.00 | 125.67 | 6.04% | |
| JP:4540 | Tsumura & Co | 3965.00 | 333.15 | 9.17% | |
| JP:2929 | Pharma Foods International Co., Ltd. | 548.00 | -215.79 | -28.25% | |
| JP:4512 | Wakamoto Pharmaceutical Co., Ltd. | 292.00 | 20.29 | 7.47% | |
| JP:4538 | Fuso Pharmaceutical Industries,Ltd. | 2168.00 | 78.62 | 3.76% |
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.
Date of analysis: Nov 17, 2026
